Moscow: A top Russian health official has said that the COVID-19 vaccine developed by the country is recommended to be used for individuals from 18 to 60 years as of now.
Vladimir Bondarev, the head of the Russian Health Ministry’s Scientific Centre for Expert Evaluation of Medicinal Products, informed that more clinical studies are needed for older people and these are expected to be carried out during post-registration clinical trials, according to a media report.
“In Russia, it is customary to certify (vaccines for) children from birth to 18 years old; adults from 18 to 60 years old; and older people who are over 60 years old. Clinical studies have now been carried out on a group of volunteers aged from 18 to 60 years old. Thus, this vaccine is now indicated for use in people from 18 to 60 years old,” Bondarev was quoted as saying by Sputnik news agency.
However, Alexander Gintsburg, the director of the Gamaleya Research Institute that developed the vaccine, claimed that he was vaccinated and he felt good, the news agency reported. He is in his late 60s.
On Tuesday, Russian President Vladimir Putin had announced that his country was the first in the world to grant regulatory approval to a COVID-19 vaccine after less than two months of human testing.
Putin had further said that one of his daughters was also given the vaccine as part of a trial.
Also Read: Necessary To Assess Russian COVID-19 Vaccine’s Safety & Effectiveness: AIIMS Director
Gaza: After being held for five months, Dania Hanatsheh—a Palestinian—who was released by Israel on…
Bhubaneswar: The Odisha government is all set to launch an extensive housing survey for the…
Bhubaneswar: Odisha is likely to experience the chilly weather conditions for another two days, the…
New Delhi: A Special Bench of the Supreme Court on Monday set March 18 as…
Bhubaneswar: A fierce gunbattle broke out between security forces and Maoists at the Odisha-Chhattisgarh border…
Bhubaneswar: After two years, Naba Das' assassination in broad daylight has again grabbed headlines with…
This website uses cookies.